2x Blend: Tesamorellin (10 mg)/Ipamorellin (5mg): 15 mg vial

Tesamorelin:

• A GHRH (growth hormone-releasing hormone) analog.

• Stimulates the pituitary gland to release endogenous growth hormone (GH).

• Leads to increased IGF-1 (insulin-like growth factor-1) production, which mediates many GH effects.

Ipamorelin:

• A ghrelin receptor agonist (GHSR agonist) and selective growth hormone secretagogue.

• Stimulates GH release from the pituitary without significantly affecting cortisol or prolactin levels.

• Often used to enhance GH pulses and recovery.

Together: The combination amplifies GH release via two pathways (GHRH and ghrelin receptor), potentially creating a synergistic effect for more robust growth hormone secretion.

• Increased lean muscle mass

• Reduced visceral fat (especially with Tesamorelin)

• Improved metabolism and lipid profile

• Enhanced recovery and sleep

• Better skin elasticity and cognitive function (anecdotally)

• Minimal desensitization (especially with Ipamorelin)

• Injection site reactions (redness, swelling, pain)

• Joint pain or stiffness

• Water retention/edema

• Tingling or numbness (carpal tunnel–like symptoms)

• Elevated IGF-1 levels (if excessive)

• Nausea or flushing

• Pregnancy or breastfeeding

• Active malignancy (GH can stimulate tumor growth)

• Known hypersensitivity to either peptide or excipients

• Diabetic patients (Tesamorelin can impair glucose tolerance)

• Untreated pituitary tumors